Apellis Pharmaceuticals Inc (APLS) - Total Liabilities
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has total liabilities worth $705.11 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Apellis Pharmaceuticals Inc (APLS) cash flow conversion to assess how effectively this company generates cash.
Apellis Pharmaceuticals Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check APLS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Apellis Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Credito Emiliano S.p.A
F:EAO
|
Germany | €61.86 Billion |
|
Youngor Group Co Ltd
SHG:600177
|
China | CN¥30.38 Billion |
|
Motilal Oswal Financial Services Limited
NSE:MOTILALOFS
|
India | Rs226.94 Billion |
|
RTL Group SA
F:RRTL
|
Germany | €4.99 Billion |
|
Inventec Corp
TW:2356
|
Taiwan | NT$255.22 Billion |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
China | CN¥7.16 Billion |
|
Loar Holdings Inc.
NYSE:LOAR
|
USA | $855.12 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥2.78 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Apellis Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Apellis Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apellis Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Apellis Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $705.11 Million | +7.40% |
| 2024-12-31 | $656.51 Million | +10.49% |
| 2023-12-31 | $594.21 Million | +0.65% |
| 2022-12-31 | $590.35 Million | -13.58% |
| 2021-12-31 | $683.10 Million | -9.64% |
| 2020-12-31 | $756.01 Million | +112.95% |
| 2019-12-31 | $355.02 Million | +734.13% |
| 2018-12-31 | $42.56 Million | +28.24% |
| 2017-12-31 | $33.19 Million | +812.04% |
| 2016-12-31 | $3.64 Million | +13.71% |
| 2015-12-31 | $3.20 Million | +195.89% |
| 2014-12-31 | $1.08 Million | +59.76% |
| 2013-12-31 | $676.96K | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more